Mr. Latte

Open-Sourcing Biology: When Tech Founders Treat Cancer Like a DevSecOps Pipeline

TL;DR Sid Sijbrandij, the co-founder who grew GitLab to over 30 million users, is applying his open-source engineering mindset to his personal battle with osteosarcoma. After exhausting standard medical treatments, he has publicly released 25TB of his medical data and is parallelizing experimental therapies. This approach highlights a growing collision between the rapid-iteration tech ethos and traditional, highly regulated medical bureaucracy.

The traditional medical system is built on sequential, highly regulated protocols designed to protect patients and establish clear clinical efficacy. However, when standard care options run out, patients facing terminal diagnoses often hit a bureaucratic wall. A new wave of tech founders is challenging this paradigm by applying software engineering principles—like open-source data sharing, maximum telemetry, and parallel processing—to personal healthcare. This collision of the “move fast” tech ethos with clinical oncology is sparking intense debates about patient agency, data silos, and medical innovation.

Key Points

Sid Sijbrandij is best known for scaling GitLab from an open-source project created in a house without running water in 2011 to a public DevSecOps giant with over 30 million registered users and 100,000 organizations. Now, as Executive Chair, he is directing that same scale-oriented mindset toward his personal battle with osteosarcoma. After reportedly exhausting standard care options and finding no available clinical trials, Sijbrandij launched the Sijbrandij Foundation to fund new cancer treatment initiatives. Taking an “information maximalist” approach, he has published 25TB of his personal medical data via publicly readable Google Cloud buckets. His self-directed strategy involves running maximum diagnostics and testing new treatments in parallel, fundamentally treating his own biology like a complex, open-source repository. While his specific medical outcomes and the efficacy of these new treatments remain unverified in peer-reviewed literature, his approach mirrors the rapid iteration cycles that defined GitLab’s success.

Technical Insights

From a software engineering perspective, Sijbrandij is applying a DevSecOps pipeline mentality to biological troubleshooting. In software, when a critical system fails, engineers rely on maximum telemetry, parallel debugging, and rapid deployment of patches. The traditional medical model, conversely, operates more like a rigid waterfall methodology: sequential trials, isolated data silos, and strict adherence to standard-of-care protocols to avoid catastrophic regressions (harm to the patient). By open-sourcing 25TB of his own diagnostic data, Sijbrandij is essentially inviting the global community to issue “pull requests” for his treatment plan. However, the technical tradeoff here is severe: biological systems lack a “rollback” function. While parallelizing experimental treatments might accelerate discovery, it introduces massive confounding variables, making it nearly impossible for clinicians to isolate which intervention actually worked or caused adverse side effects.

Implications

This trend of “bio-hacking” terminal illness could force the medical industry to rethink how it handles patient data and right-to-try laws. If releasing massive, unstructured datasets becomes a norm for patients with the resources to do so, it could accelerate AI-driven diagnostic tools by providing rare, high-resolution training data to researchers. However, there is a risk of hype overreaching reality, as self-directed, parallel treatments carry immense physical risks and lack the rigorous validation required to safely scale these methods to the general public. Ultimately, while tech billionaires can afford to bypass bureaucratic bottlenecks and fund bespoke therapies, the challenge remains how to democratize these rapid-iteration treatments without compromising patient safety.

As tech leaders continue to blur the lines between software engineering and biology, the definition of patient agency is evolving rapidly. Will the medical community adapt to integrate these massive, open-source patient datasets, or will the divide between standard care and self-directed experimental treatments only widen?

References

March 28, 2026 ∙ health-tech open-source devsecops bioinformatics
Need a freelance expert to plan and build your product? Available to founders, teams, and businesses from product framing through launch.
Work With Me Get in touch →